Tarsus Pharmaceuticals, Inc. (TARS)
Nasdaq: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Feb 23, 2026 | Feb 25, 2025 | Feb 27, 2024 | Mar 17, 2023 | Mar 14, 2022 | Mar 31, 2021 | · | · |
| Revenue | 451,360 | 182,953 | 17,447 | 25,816 | 57,027 | 0 | · | · |
| Research and development | 64,322 | 53,386 | 50,312 | 42,624 | 41,712 | 18,826 | 3,162 | · |
| Selling, general and administrative | 427,323 | 237,310 | 108,700 | 44,949 | · | · | · | · |
| General and administrative | · | · | · | 44,949 | 25,397 | 8,172 | 1,136 | · |
| Total operating expenses | · | · | 160,605 | 88,528 | 69,184 | 26,998 | 4,298 | · |
| Total costs and expenses | 522,329 | 303,522 | 160,605 | 88,528 | · | · | · | · |
| Operating income | -70,969 | -120,569 | -143,158 | -62,712 | -12,157 | -26,998 | -4,298 | · |
| Interest expense | 8,935 | 7,849 | 3,346 | 2,199 | 0 | · | · | · |
| Interest and investment income | 15,747 | 15,014 | 10,337 | 3,499 | · | · | · | · |
| Interest income (expense), net | · | · | 10,337 | 3,499 | 36 | 188 | -40 | · |
| Other income (expense), net | -202 | -206r | 274r | 86 | -73 | 0 | · | · |
| Total non-operating income (expense) | 6,610 | 5,015 | 7,265 | 617 | -1,615 | 188 | -371 | · |
| Income before income taxes | -64,359 | -115,554 | -135,893 | -62,095 | -13,772 | -26,810 | · | · |
| Income tax expense | 2,059 | 0 | 0 | -4 | 55 | 1 | 1 | · |
| Net income | -66,418 | -115,554 | -135,893 | -62,091 | -13,827 | -26,811 | -4,670 | -1,319 |
| Earnings per share, basic | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | · | · |
| Earnings per share, diluted | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -4.32 | -1.98 | · |
| Weighted average shares, basic | 41,784,014 | 37,604,538 | 29,383,276 | 24,619,700 | 20,554,086 | 6,207,367 | · | · |
| Weighted average shares, diluted | 41,784,014 | 37,604,538 | 29,383,276 | 24,619,700 | 20,554,086 | 6,207,367 | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 6,207,367 | 2,362,768 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted